U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07723482) titled 'ML-016 in Advanced Cancer With Lung and/or Liver Involvement' on April 28.
Brief Summary: This is an open-label, multi-center, phase 1/2 dose-escalation and dose expansion study evaluating the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of ML-016 in participants with advanced solid tumors with lung and/or liver involvement (primary or metastatic disease).
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumor With Lung and/or Liver Involvement
Intervention:
DRUG: ML-016
a pH-sensitive polymeric doxorubicin formulated in a nanoporous silicon microparticle
Recruitment S...